In addition to its prominent role in haematopoietic cancers, MCL-1 has emerged as a key player in breast cancer with high levels of MCL-1 protein in primary breast cancer samples correlating with poor patient prognosis [9–16]. This evidence concerns the gene MCL1 and hematopoietic and lymphoid cell neoplasm.